MXPA04003365A - Combinaciones que comprenden inhibidores de cox-2 y aspirina. - Google Patents

Combinaciones que comprenden inhibidores de cox-2 y aspirina.

Info

Publication number
MXPA04003365A
MXPA04003365A MXPA04003365A MXPA04003365A MXPA04003365A MX PA04003365 A MXPA04003365 A MX PA04003365A MX PA04003365 A MXPA04003365 A MX PA04003365A MX PA04003365 A MXPA04003365 A MX PA04003365A MX PA04003365 A MXPA04003365 A MX PA04003365A
Authority
MX
Mexico
Prior art keywords
cox
aspirin
inhibitors
combinations
responsitive
Prior art date
Application number
MXPA04003365A
Other languages
English (en)
Inventor
Gimona Alberto
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA04003365A publication Critical patent/MXPA04003365A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una composicion farmaceutica para el tratamiento de condiciones en mamiferos que son sensibles a inhibicion de COX-2 que comprende en combinacion un inhibidor de COX-2 y aspirina a dosis baja para uso simultaneo, secuencial o separado.
MXPA04003365A 2001-10-11 2002-10-10 Combinaciones que comprenden inhibidores de cox-2 y aspirina. MXPA04003365A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124459.9A GB0124459D0 (en) 2001-10-11 2001-10-11 Organic compounds
PCT/EP2002/011380 WO2003033001A1 (en) 2001-10-11 2002-10-10 Combinations comprising cox-2 inhibitors and aspirin

Publications (1)

Publication Number Publication Date
MXPA04003365A true MXPA04003365A (es) 2004-07-23

Family

ID=9923664

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003365A MXPA04003365A (es) 2001-10-11 2002-10-10 Combinaciones que comprenden inhibidores de cox-2 y aspirina.

Country Status (19)

Country Link
US (2) US20040235802A1 (es)
EP (1) EP1435968A1 (es)
JP (1) JP2005505606A (es)
KR (1) KR20040044891A (es)
CN (1) CN1625405A (es)
AU (1) AU2006249254A1 (es)
BR (1) BR0213181A (es)
CA (1) CA2458981A1 (es)
CO (1) CO5570661A2 (es)
GB (1) GB0124459D0 (es)
HU (1) HUP0401854A2 (es)
IL (1) IL160620A0 (es)
MX (1) MXPA04003365A (es)
NO (1) NO20041432L (es)
NZ (1) NZ532158A (es)
PL (1) PL369005A1 (es)
RU (1) RU2004114560A (es)
WO (1) WO2003033001A1 (es)
ZA (1) ZA200401302B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US7338971B2 (en) 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
WO2003084518A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
AU2003248642A1 (en) 2002-06-11 2003-12-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
US20080242722A1 (en) * 2004-01-27 2008-10-02 Claude Dufresne Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events
CA2609618C (en) * 2005-05-24 2016-01-05 Flamel Technologies Novel acetylsalicylic acid formulations
NZ565846A (en) * 2005-07-18 2011-12-22 Horizon Therapeutics Inc Medicaments containing famotidine and ibuprofen and administration of same
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
EP2063873A2 (en) * 2006-08-31 2009-06-03 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
US9757529B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN104173359B (zh) * 2014-09-05 2017-05-03 罗国安 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
US10272107B2 (en) * 2017-09-05 2019-04-30 Kenneth O. Russell Method for treating inflammatory brain disorders and traumatic brain injury
US10586872B2 (en) * 2018-07-03 2020-03-10 International Business Machines Corporation Formation of wrap-around-contact to reduce contact resistivity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743596A (en) * 1987-06-16 1988-05-10 Lapin Alfred R Anti-arthritic preparation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
JP2003516353A (ja) * 1999-12-08 2003-05-13 ファルマシア コーポレイション ヴァルデコキシブ組成物
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
US8680081B2 (en) * 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine

Also Published As

Publication number Publication date
WO2003033001A1 (en) 2003-04-24
RU2004114560A (ru) 2005-05-20
CN1625405A (zh) 2005-06-08
NO20041432D0 (no) 2004-04-05
GB0124459D0 (en) 2001-12-05
CA2458981A1 (en) 2003-04-24
CO5570661A2 (es) 2005-10-31
AU2006249254A1 (en) 2007-01-04
BR0213181A (pt) 2004-08-31
NZ532158A (en) 2006-04-28
US20040235802A1 (en) 2004-11-25
HUP0401854A2 (hu) 2004-12-28
JP2005505606A (ja) 2005-02-24
IL160620A0 (en) 2004-07-25
EP1435968A1 (en) 2004-07-14
US20080027032A1 (en) 2008-01-31
KR20040044891A (ko) 2004-05-31
ZA200401302B (en) 2005-01-04
PL369005A1 (en) 2005-04-18
NO20041432L (no) 2004-06-28

Similar Documents

Publication Publication Date Title
MXPA04003365A (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina.
WO2003042246A3 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
GB0010183D0 (en) Inhibitors of dipeptidyl peptidase IV
HUP0202593A3 (en) Benzophenones as inhibitors of reverse transcriptase
IL158559A (en) Use of 5-lipoxygenase inhibitors for the preparation of a pharmaceutical composition for treating acne
TW200517145A (en) Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
HUP0300563A3 (en) Inhibitors of dipeptidyl peptidase iv, pharmaceutical compositions containing them and their use
PL370220A1 (en) Inhibitors of dipeptidyl peptidase iv
ZA200108617B (en) Use of PDEV inhibitors for improved fecundity in mammals.
AU2003234257A1 (en) Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
PT1487541E (pt) Utilização de inibidores de il-8 para o tratamento e/ou prevenção de doenças vasculares periféricas
WO2001085201A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
MXPA03000694A (es) Nuevo uso de los inhibidores de lipasa.
TW200510397A (en) Conjugated complement cascade inhibitors
TR200502508T2 (tr) IL-18 İnhibitörlerinin kullanımı.
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
AP2003002719A0 (en) Use of cox-2 inhibitors for preventing immunodeficiency
EP1099442A3 (en) Methods of administering apo B-secretion/MTP inhibitors
WO2003004006A8 (en) Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
IL139144A0 (en) Mycobacterial inhibitors
AU2001285334A1 (en) Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
WO2002096516A8 (en) Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease
AU1212002A (en) Use of lipase inhibitors